BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 27931719)

  • 1. A potential pitfall in evaluating HER2 immunohistochemistry for gastric signet ring cell carcinomas.
    Woo CG; Ho WJ; Park YS; Park SR; Ryu MH; Jung HY; Kang YK
    Pathology; 2017 Jan; 49(1):38-43. PubMed ID: 27931719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3).
    Seo S; Ryu MH; Park YS; Ahn JY; Park Y; Park SR; Ryoo BY; Lee GH; Jung HY; Kang YK
    Gastric Cancer; 2019 May; 22(3):527-535. PubMed ID: 30386954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morphological features and mucin expression profile of breast carcinomas with signet-ring cell differentiation.
    Bartosch C; Mendes N; Rios E; Rodrigues M; Eloy C; Reis CA; Amendoeira I
    Pathol Res Pract; 2015 Aug; 211(8):588-95. PubMed ID: 26092598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor Heterogeneity in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Assessed by CT Texture Analysis: Association with Survival after Trastuzumab Treatment.
    Yoon SH; Kim YH; Lee YJ; Park J; Kim JW; Lee HS; Kim B
    PLoS One; 2016; 11(8):e0161278. PubMed ID: 27517841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab Specific Epitope Evaluation as a Predictive and Prognostic Biomarker in Gastric Cancer Patients.
    Koh J; Nam SK; Lee YW; Kim JW; Lee KW; Ock CY; Oh DY; Ahn SH; Kim HH; Kang KW; Kim WH; Lee HY; Lee HS
    Biomolecules; 2019 Nov; 9(12):. PubMed ID: 31779184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast metastasis of gastric signet-ring cell carcinoma: a case report and literature review.
    He CL; Chen P; Xia BL; Xiao Q; Cai FL
    World J Surg Oncol; 2015 Mar; 13():120. PubMed ID: 25890325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2 testing in paired biopsy and excision specimens of gastric cancer: the reliability of the scoring system and the clinicopathological factors relevant to discordance.
    Huang SC; Ng KF; Lee SE; Chen KH; Yeh TS; Chen TC
    Gastric Cancer; 2016 Jan; 19(1):176-82. PubMed ID: 25512144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples.
    Zhu Y; Lu D; Lira ME; Xu Q; Du Y; Xiong J; Mao M; Chung HC; Zheng G
    Exp Mol Pathol; 2016 Apr; 100(2):287-93. PubMed ID: 26626802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of mucin expression profiles in breast carcinoma with signet ring cells: a clinicopathological study.
    Ohashi R; Hayama A; Yanagihara K; Yamashita K; Sakatani T; Takei H; Naito Z
    Diagn Pathol; 2016 Nov; 11(1):131. PubMed ID: 27846863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer.
    Wang H; Li B; Liu Z; Gong J; Shao L; Ren J; Niu Y; Bo S; Li Z; Lai Y; Lu S; Gao J; Shen L
    Eur J Cancer; 2018 Jan; 88():92-100. PubMed ID: 29207318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of intratumoral heterogeneity of HER2 expression between primary tumor and multiple organ metastases in gastric cancer: Clinicopathological study of three autopsy cases and one resected case.
    Saito T; Kondo C; Shitara K; Ito Y; Saito N; Ikehara Y; Yatabe Y; Yamamichi K; Tanaka H; Nakanishi H
    Pathol Int; 2015 Jun; 65(6):309-17. PubMed ID: 25828363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice.
    Grillo F; Fassan M; Sarocchi F; Fiocca R; Mastracci L
    World J Gastroenterol; 2016 Jul; 22(26):5879-87. PubMed ID: 27468182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer.
    Kim JW; Kim JH; Im SA; Kim YJ; Han HS; Kim JS; Lee KH; Kim TY; Han SW; Jeon YK; Oh DY; Kim TY; Park IA
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):109-15. PubMed ID: 23673443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2-testing in 538 consecutive breast cancer cases using FISH and immunohistochemistry.
    Kovács A; Stenman G
    Pathol Res Pract; 2010 Jan; 206(1):39-42. PubMed ID: 19819642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest in breast carcinoma.
    Ainsworth R; Bartlett JM; Going JJ; Mallon EA; Forsyth A; Richmond J; Angerson W; Watters A; Dunne B
    J Clin Pathol; 2005 Oct; 58(10):1086-90. PubMed ID: 16189156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of cell adhesion molecule 1 in gastric neck and base glandular cells: Possible involvement in peritoneal dissemination of signet ring cells.
    Kimura R; Yoneshige A; Hagiyama M; Otani T; Inoue T; Shiraishi N; Yanagihara K; Wakayama T; Ito A
    Life Sci; 2018 Nov; 213():206-213. PubMed ID: 30312702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinicopathologic and immunohistochemical study on early gastric signet-ring cell carcinoma].
    Xiong ZF; Xiao H; Tan YS
    Zhonghua Bing Li Xue Za Zhi; 2010 Jul; 39(7):442-6. PubMed ID: 21055171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differentiating breast carcinoma with signet ring features from gastrointestinal signet ring carcinoma: assessment of immunohistochemical markers.
    Hui Y; Wang Y; Nam G; Fanion J; Sturtevant A; Lombardo KA; Resnick MB
    Hum Pathol; 2018 Jul; 77():11-19. PubMed ID: 29317235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1).
    Park SR; Park YS; Ryu MH; Ryoo BY; Woo CG; Jung HY; Lee JH; Lee GH; Kang YK
    Eur J Cancer; 2016 Jan; 53():42-50. PubMed ID: 26693898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.